Patent search ap:("SHANGHAI INSTITUTE OF MATERIA MEDICA Page CHINESE ACADEMY OF SCIENCES") AND inv:"Meiyu Geng"

11.

发明授权
Compound having ERK kinase inhibitory activity and use thereof 有权

公开(公告)号：US11465984B2

公开(公告)日：2022-10-11

申请号：US16652148

申请日：2018-09-29

Applicant: SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Lei Li , Meiyu Geng , Ying Huang , Jian Ding , Qiong Zhang , Min Huang , Shuai Tang , Ning Shen , Yi Chen

IPC: C07D401/14 , C07D403/14 , C07D405/14

Abstract: The invention relates to a compound of formula (I): wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.

12.

发明授权
Use of mannuronic diacid composition in treatment of pain 有权

公开(公告)号：US11406653B2

公开(公告)日：2022-08-09

申请号：US17256950

申请日：2019-06-28

Applicant: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Meiyu Geng , Xianliang Xin , Zhenqing Zhang , Jian Ding

IPC: A61P25/06 , A61K31/715 , A61K31/7032 , A61K31/702 , A61P25/04 , A61K31/7004 , A61K31/7016

Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of pain.

13.

发明授权
Aryl-2,2′-tandem bisthiazole compound and preparation method and use thereof 有权

公开(公告)号：US10766889B2

公开(公告)日：2020-09-08

申请号：US16329336

申请日：2017-08-24

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun Nan , Jia Li , Jian Ding , Meiyu Geng , Yangming Zhang , Yi Chen , Yubo Zhou , Chaojun Gong , Mingbo Su , Anhui Gao

IPC: C07D277/56 , C07D277/60 , C07D417/04 , A61P35/02 , A61K31/427 , A61P35/00

Abstract: The invention describes an aryl-2,2′-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2′-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.

14.

发明授权
Pyrido-azaheterecydic compound and preparation method and use thereof 有权

公开(公告)号：US10710996B2

公开(公告)日：2020-07-14

申请号：US15575903

申请日：2016-05-23

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Yaqiu Long , Meiyu Geng , Zhongliang Xu , Jing Ai

IPC: C07D471/04 , A61K31/501 , A61K31/4985 , A61K31/4375 , A61K31/496 , A61K31/4545 , A61K31/444 , A61K31/5377 , A61P35/00

Abstract: The present invention discloses a pyrido-azacyclic compound represented by formula I, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, a preparation process thereof and a composition comprising the compound, and a use thereof as a multi-target protein kinase inhibitor in the preparation of a medicament for the treatment of diseases that are associated with protein kinase, especially c-Met, such as cancer and the like. The compound represented by formula I has potent inhibitory activity on tumor cells with overexpression of c-Met kinase, can effectively target c-Met-mediated signaling pathway, and can be used in the treatment of diseases such as cancer and the like that is caused by the overexpression of c-Met kinase.

15.

发明申请
PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF 审中-公开

公开(公告)号：US20190292183A1

公开(公告)日：2019-09-26

申请号：US16463868

申请日：2017-11-24

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Ao Zhang , Jian Ding , Hua Xie , Zilan Song , Yu Xue , Linjiang Tong , Meiyu Geng

IPC: C07D471/14 , C07D487/14 , A61P35/00

Abstract: The present disclosure relates to a Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method thereof and use thereof. The compounds of the present invention have good inhibitory activities against BTK at the molecular and cellular levels. Importantly, the compounds of the present invention have low activity against Ramos cells of normal human B lymphoma cells, and have high activity against BTK-sensitive human diffuse large B lymphoma TMD8 cells, indicating that these type of compounds with novel structural are highly selective, off-target phenomenon and corresponding side effects are low. Thus it is a selective inhibitor of BTK with development potential.

16.

发明授权
Certain protein kinase inhibitors 有权

公开(公告)号：US10328060B2

公开(公告)日：2019-06-25

申请号：US15523315

申请日：2015-11-01

Applicant: Shanghai Fochon Pharmaceutical Co., Ltd. , Shanghai Institute of Materia Medica Chinese Academy of Sciences , Chongqing Fochon Pharmaceutical Co., Ltd.

Inventor： Xingdong Zhao , Jian Ding , Linghua Meng , Meiyu Geng , Tongshuang Li , Zuwen Zhou , Ling Chen , Qihong Liu , Xianlong Wang , Lijun Yang , Yue Rong , Rui Tan , Chuiliang Yu , Lihua Jiang , Yanxin Liu , Li Linghu , Jing Sun , Weibo Wang

IPC: C07D519/00 , A61K31/437 , A61K45/06 , A61K31/4375 , A61K31/505 , A61K31/52

Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

17.

发明申请
FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF 有权
Title translation: 五元共聚物氟化物吡啶化合物，其制备方法及其用途

公开(公告)号：US20160137640A1

公开(公告)日：2016-05-19

申请号：US14895832

申请日：2014-06-18

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD.

Inventor： Jingkang Shen , Meiyu Geng , Jian Ding , Bing Xiong , Jing Al , Yuchi Ma , Xin Wang , Xia Peng , Yuelei Chen , Danqi Chen , Tao Meng , Lanping Ma , Yinchun Ji

IPC: C07D471/04 , C07D519/00

CPC classification number: C07D471/04 , C07D487/04 , C07D495/04 , C07D519/00

Abstract: This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumours associated with abnormal protein tyrosine kinase.

Abstract translation: 本发明提供一类如下式（X）所示的五元杂环稠合吡啶化合物，其药学上可接受的盐或药学上可接受的溶剂合物，其制备方法，含该化合物的药物组合物，以及该化合物的用途在制备用于预防和/或治疗与异常蛋白酪氨酸激酶相关的疾病和肿瘤的药物中。

18.

发明申请
USE OF MANNURONIC ACID OLIGOSACCHARIDES OR COMPOSITION COMPRISING SAME IN TREATMENT OF TH1-DOMINANCE RELATED DISEASES 有权

公开(公告)号：US20220362271A1

公开(公告)日：2022-11-17

申请号：US17631731

申请日：2020-08-05

Applicant: SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Meiyu Geng , Guangqiang Sun , Xinyi Wang , Jing Zhang , Teng Feng

IPC: A61K31/702 , A61K31/734 , A61P19/02 , A61P25/28 , A61P5/16 , A61P5/50

Abstract: A use that relates to mannuronic acid oligosaccharides or a composition comprising same in the treatment of Th1-dominance related diseases. The Th1-dominance related diseases may be selected from Multiple Sclerosis, Crohn's disease, Type I Diabetes, Rheumatoid Arthritis, Hashimoto's thyroiditis, vitiligo, Sjögren's Syndrome, Polycystic ovary syndrome, Celiac Disease and Grave's disease, preferably from Multiple Sclerosis, Crohn's disease and Rheumatoid Arthritis.